US suspends chikungunya vaccine over side effects

PARIS, Aug 25 (AFP): US health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of "serious adverse events", the drug's French maker said Monday.

Ixchiq is one of just two vaccines approved by the US Food and Drug Administration for the mosquito-spread virus, which mainly occurs in tropical and subtropical regions but has recently been discovered to countries worldwide.

French company Valneva obtained US approval for the vaccine in 2023, but reports of side effects have prompted reviews in particular over its use in older patients, including by the European Medicines Agency this year.

"The suspension of the license is effective immediately," Valneva said of the FDA order issued Friday.